Ceribell's AI-based electroencephalogram (EEG) system reduces ICU stays and the number of patients discharged with disabilities compared to standard EEG.
The research data is Neurointensive Care The Journal found that use of Ceribell's system in the ICU reduced the average length of hospital stay by 4.1 days compared with traditional EEG. Additionally, it reduced the number of patients discharged with low scores on the modified Rankin scale, which measures functional impairment, by 18 percentage points.
This study is a propensity score-matched subanalysis of 283 patient records from the SAFER-EEG trial, a retrospective study of adult patients monitored with EEG during hospitalization.
An EEG is a medical test that measures electrical activity in the brain. A standard EEG involves placing electrodes on the scalp to detect and record signals generated by the brain. The data is then interpreted by a trained neurologist, which can delay diagnosis and treatment.
The Ceribell system uses AI to analyze EEG data in real time, providing immediate feedback to help identify seizure activity and other abnormalities, which is especially useful when a neurologist is not immediately available. In the study, the system significantly sped up EEG acquisition, reducing the average time from 25.3 hours to 5.9 hours.
The system first received U.S. Food and Drug Administration (FDA) clearance in 2017 and is commercially available in the U.S. According to Ceribell, the latest generation of Ceribell's AI algorithm, called Clarity, is the first and only device to receive 510(k) clearance for the diagnosis of status epilepticus via EEG.
Access the most comprehensive company profiles on the market from GlobalData. Save time on research and gain a competitive advantage.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profiles, but because we want you to make the most beneficial decision for your business, we are offering free samples that you can download by submitting the form below.
From GlobalData
The California-based company closed a $50 million equity funding round led by Ally Bridge Group in September 2022, following a $53 million Series C round it raised the previous year. Celibel said it will use the funds to continue commercial expansion and further development of its EEG system.
“These study findings highlight the critical importance of early assessment with point-of-care EEG and how the Ceribell system enables healthcare professionals to improve patient care while reducing hospital length of stay and the burden on hospital staff,” said Jane Chao, CEO of Ceribell.
According to GlobalData, AI will be a key driver of innovation in medical devices, with the market for AI platforms for the medical device industry predicted to reach $1.2 billion by 2027, up from $336 million in 2022.
Last month, US-based medical device maker Zeto received 510(k) clearance from the FDA for its Zeto ONE EEG system, which can be used in hospitals, at home, ambulances and air transport environments. Data, including AI-enabled real-time seizure notifications, is streamed to Zeto Cloud for real-time remote interpretation by neurologists.
